Crinetics Pharmaceuticals (CRNX) Current Deferred Revenue (2022 - 2026)

Crinetics Pharmaceuticals has reported Current Deferred Revenue for 5 years, with the latest figure at $1.3 million in Q1 2026.

• For the quarter ending Q1 2026, Current Deferred Revenue fell 80.5% year-over-year to $1.3 million; the trailing twelve-month figure through Mar 2026 stood at $1.3 million (down 80.5% YoY), and the FY2025 full-year result was $1.2 million, down 82.05% from the prior year.
• Current Deferred Revenue for Q1 2026 stood at $1.3 million, up from $1.2 million in the prior quarter.
• The five-year high for Current Deferred Revenue was $9.4 million in Q2 2022, with the low at $1.2 million in Q4 2025.
• Average Current Deferred Revenue over 5 years is $4.8 million, with a median of $6.5 million recorded in 2025.
• Year-over-year, Current Deferred Revenue surged 185.88% in 2023 and slumped 82.05% in 2025.
• Tracing CRNX's Current Deferred Revenue over 5 years: stood at $8.3 million in 2022, then slipped by 18.4% to $6.8 million in 2023, then increased by 1.09% to $6.9 million in 2024, then tumbled by 82.05% to $1.2 million in 2025, then rose by 2.91% to $1.3 million in 2026.
• The last three Current Deferred Revenue figures came in at $1.3 million (Q1 2026), $1.2 million (Q4 2025), and $1.6 million (Q3 2025), per Business Quant data.

Peer Comparison